High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast
| Autor: | Tauer Kw, B McAneny, Buckner Cd, L Lewkow, B Zhen, Lee S. Schwartzberg, C H Weaver, WH West, R Birch |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Breast Neoplasms Hematopoietic stem cell transplantation ThioTEPA Adenocarcinoma Inflammatory breast cancer Disease-Free Survival Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Staging Transplantation Chemotherapy business.industry Hematopoietic Stem Cell Transplantation Induction chemotherapy Hematology Middle Aged medicine.disease Combined Modality Therapy Nitrogen mustard Hematopoietic Stem Cell Mobilization Surgery chemistry Chemotherapy Adjuvant Female business Thiotepa medicine.drug |
| Zdroj: | Bone marrow transplantation. 24(9) |
| ISSN: | 0268-3369 |
| Popis: | The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with cyclophosphamide, thiotepa and carboplatin (CTCb) with peripheral blood stem cell (PBSC) support. All patients received the same total amount of chemotherapy but there were differences in the sequence of therapy: 15 received induction chemotherapy, chemotherapy mobilization of PBSC and CTCb after surgery (adjuvant group) while 41 received induction chemotherapy with (n = 17) or without (n = 24) chemotherapy for mobilization of PBSC prior to surgery and CTCb after surgery (neoadjuvant group). Median time from diagnosis to HDC was 5.5 months (range 3.5-12.5). Fifty-one patients (91%) required admission to the hospital following HDC for a median of 11 days (range 5-25). There were two (4%) infectious deaths after HDC. Twenty-four patients (43%) have relapsed at a median of 18 months (range 8-50) from diagnosis resulting in death in 34%. The probabilities of overall (OS) and event-free survival (EFS) at 3 years for all 56 patients were 0.72 and 0.53, respectively, with a median follow-up of 44 months (range 15-76) from diagnosis. There were no differences in OS, EFS or patterns of relapse between patients in the adjuvant or neoadjuvant groups. These sequences of combined modality therapy incorporating HDC are comparable or superior to other intensive approaches for the treatment of IBC. Further improvements will be necessary to decrease systemic recurrences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|